白细胞免疫球蛋白样受体B4(LILRB4)是LILR家族中的抑制性受体,主要在骨髓来源的正常和恶性人细胞上表达。通过与配体结合,LILRB4被激活,随后将衔接子招募到细胞质免疫受体酪氨酸抑制基序,以启动不同的信号级联,因此在生理和病理状况中起着重要作用,包括自身免疫性疾病,微生物感染,和癌症。在正常骨髓细胞中,LILRB4调节固有细胞活化和分化。在疾病相关或恶性骨髓细胞中,LILRB4与疾病严重程度或患者生存显着相关,并抑制T细胞,从而参与各种疾病的发病机制。总之,LILRB4作为骨髓细胞的免疫检查点,可能是各种人类免疫疾病的有希望的治疗靶点。尤其是癌症免疫疗法。
Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an inhibitory receptor in the
LILR family mainly expressed on normal and malignant human cells of myeloid origin. By binding to ligands, LILRB4 is activated and subsequently recruits adaptors to cytoplasmic immunoreceptor tyrosine inhibitory motifs to initiate different signaling cascades, thus playing an important role in physiological and pathological conditions, including autoimmune diseases, microbial infections, and cancers. In normal myeloid cells, LILRB4 regulates intrinsic cell activation and differentiation. In disease-associated or malignant myeloid cells, LILRB4 is significantly correlated with disease severity or patient survival and suppresses T cells, thereby participating in the pathogenesis of various diseases. In summary, LILRB4 functions as an immune checkpoint on myeloid cells and may be a promising therapeutic target for various human immune diseases, especially for cancer immunotherapy.